Nimodipine is a dihydropyridine calciumchannel blocker with pronounced cerebrovascular selectivity, used clinically to protect the brain from ischemic injury by preferentially relaxing cerebral arterial smooth muscle while limiting systemic hypotension. Its primary indication is for the prevention and treatment of neurological deficits following aneurysmal subarachnoid haemorrhage (SAH), where nimodipine reduces the risk of delayed cerebral vasospasm and associated poor neurological outcomes. Clinical evidence demonstrates a clinically meaningful reduction in severe neurological deficits and mortality in SAH populations when nimodipine is administered according to guidelinerecommended regimens.

Pharmaceutically, nimodipine poses formulation and stability challenges. The active substance is highly lipophilic, poorly watersoluble and photolabile, making control of crystal form, particle size distribution and dissolution behaviour critical for consistent bioavailability. Production and formulation therefore require tight environmental and process controls, lightprotective measures, and validated methods to ensure uniformity and reproducible dissolution profiles across batches. Stability risks include photodegradation and solventrelated polymorphic shifts, which must be characterised by forceddegradation studies and monitored in a structured stability programme.

Formulation strategies to address these challenges include lipidbased carriers, solubilisingexcipients, solid dispersions and advanced delivery systems (nanoparticles, microemulsions, lyophilised forms). Selection of approach should be driven by target product profile and CMC considerations, with emphasis on maintaining crystalline integrity, optimising dissolution and minimising variability in clinical performance. Analytical control should cover identity, assay, related substances, photostability, dissolution and polymorphism, supported by validated analytical procedures and appropriate inprocess controls.

MediPharm perspective

MediPharm treats nimodipine as a model compound at the interface of complex formulation science and precision GMP manufacturing. The company applies targeted process design, lightprotected handling, solvent control and particle engineering to maintain product quality. MediPharm’scapabilities include formulation development (including lipid and soliddispersion approaches), lyophilisation, GMP production with lightprotected packaging, and comprehensive CMC documentation comprising validated analytical methods, forceddegradation data, stability datasets and regulatory filingready modules suitable for EU submissions.

Sources:

Balaev, A.N., Osipov, V.N. and Fedorov, V.E. (2012) ‘Development of Nimodipine Production Technology’, Pharmaceutical Chemistry Journal, 46(5), pp. 285-287. doi:10.1007/s11094-012-0780-6.
Das, J.M. (2024) Nimodipine, StatPearls [Internet]. 
Available at: https://www.ncbi.nlm.nih.gov/books/NBK534870/